Hansa Biopharma Unveils Promising Five-Year Follow-Up Data for Imlifidase in Kidney Transplantation at ESOT Congress 2025
London, UK – June 30, 2025 – Hansa Biopharma, a pioneer in enzyme technology for enzyme replacement therapies, today announced the presentation of compelling positive outcomes from a five-year follow-up study of its novel enzyme imlifidase in the context of kidney transplantation. The findings were shared at the prestigious European Society for Organ Transplantation (ESOT) Congress 2025, held in London.
The presented data represents a significant milestone in the ongoing evaluation of imlifidase, a sphingomyelinase enzyme developed to enable antibody removal in organ transplantation. The five-year follow-up provides crucial long-term insights into the efficacy and safety profile of imlifidase when used in kidney transplant recipients.
While specific details of the study’s findings were presented at the congress, the announcement highlights the generally positive trajectory observed over the five-year period. This extended follow-up is particularly important in transplantation, where long-term graft survival and patient well-being are paramount. The study’s outcomes are anticipated to offer valuable information for clinicians and researchers working to improve the success rates of kidney transplants, especially in highly sensitized patients for whom transplantation can be challenging.
Imlifidase has been developed by Hansa Biopharma with the aim of facilitating transplantation for a broader patient population by selectively cleaving immunoglobulin G (IgG) antibodies. This mechanism of action is designed to reduce the risk of antibody-mediated rejection, a significant barrier to successful organ transplantation.
The presentation at the ESOT Congress 2025 underscores Hansa Biopharma’s commitment to advancing the field of transplantation immunology. By sharing these long-term follow-up results, the company aims to contribute to the scientific understanding of imlifidase’s potential to positively impact the lives of kidney transplant recipients. The congress, a leading platform for organ transplantation professionals, provides an ideal venue for disseminating such important clinical data and fostering discussion within the global scientific community.
Further details regarding the study’s methodologies, specific efficacy endpoints, and safety observations are expected to be released or discussed following the congress presentation. The positive outcomes from this five-year follow-up study are a testament to the dedicated research and development efforts at Hansa Biopharma and offer renewed hope for the future of kidney transplantation.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London’ at 2025-06-30 06:17. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.